Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors

Completed · Not applicable

Conditions studied: Prostate Cancer, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Localized Prostate Carcinoma

In brief

The primary purpose of this study is to evaluate the feasibility and safety of MRI-guided focal laser ablation (Laser-Induced Interstitial Thermal Therapy, LITT) to treat low-risk native prostate cancer.

Key facts

Study ID

NCT02600156

Run by

Mayo Clinic

People needed

7

Starts

2015-09-01

Expected to finish

2025-12-09

Last updated by the study team

2025-12-17

Who can join

Age: 45 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male, 45 years of age or older.
• Diagnosis of prostate adenocarcinoma.
• Clinical stage T1c or T2a.
• Gleason score of 7 (3+4 or 4+3) or Intermediate risk Gleason 6
• PSA less than or equal to 20 ng/mL
• Three or fewer biopsy locations with prostate cancer which correlate with MRI findings.
• No lesion > or = 2cm
• One, two, or three tumor suspicious regions identified on multiparametric MRI
• No definite radiographic indication of extra-capsular extension.
• Estimated survival of 5 years or greater, as determined by treating physician.
• Tolerance for anesthesia/sedation.
• Ability to give informed consent.

You may not qualify if…

• Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.
• History of other primary non-skin malignancy within previous three years.

Where it is running

• Mayo Clinic in Minnesota — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.